We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ocular Therapeutix Inc | NASDAQ:OCUL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.01 | 20.12% | 6.03 | 5.88 | 6.04 | 5.95 | 4.93 | 5.06 | 3,479,674 | 00:45:54 |
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will deliver a live presentation on the Company's pipeline and business activities and will be available to participate in one-on-one meetings with investors registered to attend the conference.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link to register for the conference (www.hcwevents.com). Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: H. C. Wainwright Annual Global Life Sciences Conference
Presentation Date: April 9, 2018
Presentation Time: Monday, 2:35PM UTC
Location: Salon Atlantique; Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, a sustained release travoprost intracameral implant for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These implants include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180322006265/en/
InvestorsOcular TherapeutixDonald NotmanChief Financial Officerdnotman@ocutx.comorWestwicke PartnersChris BrinzeyManaging Directorchris.brinzey@westwicke.comorMediaOcular TherapeutixScott CorningSenior Vice President, Commercialscorning@ocutx.com
1 Year Ocular Therapeutix Chart |
1 Month Ocular Therapeutix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions